In the News | Friends of Cancer Research

You are here

In the News

Wall Street Journal- Torti’s Farewell Memo to FDA Staff: ‘Take the FDA Back’

By Sarah Rubenstein Not long after sending out a memo warning FDA staff about leaking confidential information — and then seeing the memo get leaked —

Frank Torti sent out a farewell message to the staff on Friday. That, too, was leaked, and it offered some interesting words on the state of the agency:

FDA Week- Sentinel Could Help Choose Comparative Effectiveness Projects

 By John Wilkerson, FDA’s Sentinel Initiative and other large data networks should be used to choose comparative effectiveness research projects, a cancer research advocacy groups says.

 Many believe the government’s designs on comparative effectiveness are at odds with FDA’s emphasis on personalized medicine, so the Friends of Cancer Research is looking into how the two approaches could inform each other and not be seen as opposites. 

Houston Chronicle- Now’s time to reinvigorate country’s War on Cancer


Cancer is a relentless disease. It doesn’t discriminate between men and women, wealthy or poor, the elderly or the young.

Washington Post- After Cancer, Lawmaker Urges Tests

 By Richard Leiby, She didn't cry on "Good Morning America." She didn't cry when she talked to the local press. But yesterday, surrounded by a sisterhood of other breast cancer survivors, Rep. Debbie Wasserman Schultz stood looking so vulnerable and human

 -- so unlike a typical member of Congress -- at a lectern in a small Capitol dining room, and broke down repeatedly.

Dow Jones- Roche's Herceptin Extends Life In Aggressive Stomach Cancer

By Hans Schoemaker

ZURICH -(Dow Jones)- Drugmaker Roche Holding AG

(ROG.VX) said Wednesday that new data shows its breast cancer drug Herceptin also shows benefits when used to treat aggressive stomach cancer.   The results, from ToGA, a large international Phase III trial, show that Herceptin significantly prolongs the lives of patients with HER2-positive advanced stomach cancer.

"This is definitely good news," said Karl-Heinz Koch, an analyst at Helvea, who rates the stock at buy.

Comparison Shopping for Medicine

Obama's Stimulus Package Funds Research on Cutting Costs By Ceci Connolly

What's best for insomnia -- Lunesta, at about $6 a pill, or Zolpidem, at $2?

Should a man with prostate cancer choose radiation, surgery or "watchful waiting"?

Is it better to operate on a bad knee or get an injection of the joint fluid known as Visco.

To help doctors and patients decide, President Obama has dedicated $1.1 billion in the economic stimulus package for federal agencies to oversee studies on the merits of competing medical treatments.

Obama to tap Hamburg to run FDA

By Lisa Richwine, WASHINGTON (Reuters) - President Barack Obama is set to nominate former New York City health chief Margaret Hamburg as commissioner of the Food and Drug Administration, people with knowledge of the matter said on Thursday.

Hamburg, if confirmed by the Senate, will take over an agency stung by a deadly salmonella outbreak and a series of drug safety problems over the past several years.

FDA Pick Was NYC Health Chief

Physician's Chief Deputy Would Be Baltimore Commissioner

By Rob Stein and Lyndsey Layton

The Obama administration has tapped Margaret A. Hamburg, a physician and former New York City health commissioner

 with an interest in bioterrorism, to run the struggling Food and Drug Administration, according to people familiar with the choice.

RPM Report - FDA Commissioner Hamburg: Administration Closing In On Official Announcement

By Ramsey Baghdadi

Former New York City Health Commissioner Margaret Hamburg is preparing for confirmation hearings with the White House set to announce her nomination as FDA Commissioner shortly.

Baltimore Health Commissioner Joshua Sharfstein will serve as Hamburg’s principal deputy commissioner.

Wall Street Journal - Obama, Health-Care Players Agree to Seek Overhaul

By Laura Meckler

WASHINGTON -- President Barack Obama said Thursday that he would fight for an overhaul of the U.S. health-care system this year, and legislators and lobbyists gathered at the White House promised to help.